Cetera Advisor Networks LLC Nektar Therapeutics Transaction History

Cetera Advisor Networks LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$0.49 - $0.96 $5,942 - $11,642	12,128 New	12,128 $11,000
Q3 2020 Nov 13, 2020	SELL	$16.59 - $24.79 $88,408 - $132,105	-5,329 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$16.86 - $23.44 $89,846 - $124,911	5,329 New	5,329 $123,000
Q3 2019 Nov 06, 2019	SELL	$16.91 - $36.27 $153,035 - $328,243	-9,050 Closed	0 $0
Q2 2019 Aug 12, 2019	SELL	$31.0 - $36.3 $4,619 - $5,408	-149 Reduced 1.62%	9,050 $325,000
Q1 2019 May 06, 2019	SELL	$31.58 - $46.35 $5,431 - $7,972	-172 Reduced 1.84%	9,199 $314,000
Q4 2018 Feb 15, 2019	BUY	$30.43 - $56.65 $15,215 - $28,325	500 Added 5.64%	9,371 $312,000
Q3 2018 Nov 14, 2018	BUY	$46.46 - $68.49 $169,625 - $250,056	3,651 Added 69.94%	8,871 $535,000
Q2 2018 Aug 14, 2018	BUY	$46.25 - $104.45 $46,943 - $106,016	1,015 Added 24.14%	5,220 $258,000
Q1 2018 May 09, 2018	BUY	$57.4 - $108.44 $241,367 - $455,990	4,205 New	4,205 $449,000

145

139M

32.6K

14.1K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $174M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Cetera Advisor Networks LLC, based on Form 13F filings with the SEC.

Stay updated on Cetera Advisor Networks LLC with notifications on news.